Table. Demographic and Clinical Characteristics of Study Participants, Stratified by Immune Response to the 2 Doses of SARS-CoV-2 mRNA Vaccine.
| No. (%) by postvaccination antibody response | P value | |||
|---|---|---|---|---|
| Dose 1− Dose 2− |
Dose 1− Dose 2+ |
Dose 1+ Dose 2+ |
||
| No. | 301 (46) | 259 (39) | 98 (15) | |
| Age category, ya | ||||
| 18-39 | 46 (41) | 35 (31) | 32 (28) | .002b |
| 40-59 | 86 (42) | 94 (46) | 26 (13) | |
| ≥60 | 169 (50) | 129 (38) | 40 (12) | |
| Sexc | ||||
| Female | 170 (45) | 152 (40) | 58 (15) | .92d |
| Male | 124 (46) | 103 (39) | 40 (15) | |
| Racee | ||||
| White | 261 (45) | 228 (40) | 85 (15) | .74d |
| Black or African American | 11 (55) | 7 (35) | 2 (10) | |
| Asian or Pacific Islander | 13 (39) | 12 (36) | 8 (24) | |
| Other | 10 (48) | 8 (38) | 3 (14) | |
| Organf | ||||
| Kidney | 168 (52) | 118 (37) | 36 (11) | <.001d |
| Liver | 26 (20) | 62 (48) | 41 (32) | |
| Heart | 42 (43) | 45 (46) | 10 (10) | |
| Lung | 43 (61) | 22 (31) | 6 (8) | |
| Pancreas | 4 (80) | 1 (20) | 0 | |
| Other multiorgan | 15 (58) | 7 (27) | 4 (15) | |
| Years since transplantg | ||||
| <3 | 114 (63) | 54 (30) | 13 (7) | .001b |
| 3-6 | 69 (50) | 53 (39) | 15 (11) | |
| 7-11 | 54 (38) | 61 (43) | 26 (18) | |
| ≥12 | 62 (33) | 85 (45) | 43 (23) | |
| Maintenance immunosuppression regimen | ||||
| Includes antimetaboliteh | 268 (57) | 167 (35) | 38 (8) | <.001d |
| Does not include antimetabolitei | 33 (18) | 92 (50) | 60 (32) | |
| Vaccinej | ||||
| mRNA-1273 (Moderna) | 124 (40) | 116 (38) | 67 (22) | <.001d |
| BNT162b2 (Pfizer-BioNTech) | 175 (51) | 138 (40) | 29 (8) | |
| Enzyme immunossayk | ||||
| Roche Elecsys | 206 (44) | 188 (40) | 76 (16) | .19 |
| EUROIMMUN | 95 (51) | 71 (38) | 22 (12) | |
Missing in 1 (column 3).
Kruskal-Wallis test, treating variables (age and years since transplant) as continuous.
Missing in 11 (7 in column 2, 4 in column 3).
Fisher exact test P value.
Missing in 10 (6 in column 2, 4 in column 3). Race/ethnicity options were defined by the investigators and classified by the participants. Race/ethnicity was assessed to evaluate potential race/ethnicity differences in immune response. “Other” includes American Indian or Alaska Native, Arabic or Middle Eastern, multiracial, or chose not to answer.
Missing in 8 (3 in column 2, 4 in column 3, 1 in column 4).
Missing in 9 (2 in column 2, 6 in column 3, 1 in column 4).
Includes mycophenolate mofetil, mycophenolic acid, or azathioprine.
Includes corticosteroids, tacrolimus, cyclosporine, sirolimus, everolimus, or belatacept, but not antimetabolites.
Missing in 9 (2 in column 2, 5 in column 3, 2 in column 4).
Manufacturer cutoffs; positive ≥0.80 U/mL (Roche); positive ≥1.1 arbitrary units (EUROIMMUN).